Literature DB >> 19173680

Impact of the haplotypes of the human pregnane X receptor gene on the basal and St John's wort-induced activity of cytochrome P450 3A4 enzyme.

Xue-Ding Wang1, Jia-Li Li, Qi-Biao Su, Su Guan, Jie Chen, Jun Du, Yu-Wen He, Jun Zeng, Jin-Xin Zhang, Xiao Chen, Min Huang, Shu-Feng Zhou.   

Abstract

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: Human pregnane X receptor (PXR/NR1I2) is a key regulator of cytochrome P450 3A4. To date, there are 198 reported SNPs for the human PXR/NR1I2 gene. Some of these SNPs are found to affect the inducing ability of PXR to CYP3A4. WHAT THIS STUDY ADDS: This study, for the first time, has investigated the effect of PXR haplotype on basal and St John's wort-induced CYP3A4 activity in humans. H1/H1 of the PXR gene had weaker basal transcriptional activity but greater inducible transcriptional activity to CYP3A4 than H1/H2 and H2/H2. AIMS: Human pregnane X receptor (PXR/NR1I2) is the master regulator of CYP3A4, which metabolizes >50% of drugs on the market. This study investigated the relationship between the two most frequent haplotypes [H1 (TCAGGGGCCACC) and H2 (CCGAAAACTAAT)] of PXR and basal and St John's wort (SJW)-induced CYP3A4 activity.
METHODS: Ten healthy subjects carrying H1 and H2 haplotypes (three subjects with H1/H1, four with H1/H2 and three with H2/H2) entered this study. The 10 subjects did not carry CYP3A4*4, *5 and *6. All subjects were administrated a 300-mg SJW tablet three times daily for 14 days, and CYP3A4 activity was measured using nifedipine (NIF) as a probe. The plasma concentrations of NIF and dehydronifedipine (DNIF) were determined by a validated liquid chromatography/mass spectrometry/mass spectrometry method.
RESULTS: After administration of SJW, the AUC(0-infinity) of NIF decreased significantly, and the AUC(0-infinity) of DNIF increased significantly (P < 0.05). For H1/H2, the AUC(0-infinity) of NIF decreased by 42.4%, and the AUC(0-infinity) of DNIF increased by 20.2%; for H2/H2, the AUC(0-infinity) of NIF decreased by 47.9%, and the AUC(0-infinity) of DNIF increased by 33.0%; for H1/H1, the AUC(0-infinity) of NIF decreased by 29.0%, yet the AUC(0-infinity) of DNIF increased by 106.7%. The increase of the AUC(0-infinity) of DNIF in H1/H1 was significantly different from the other two haplotype pairs (P < 0.05). Meanwhile, before administration of SJW, the ratio of AUC(0-infinity(DNIF))/AUC(0-infinity(NIF)) was the lowest for H1/H1 (22.1%), compared with H1/H2 (58.7%) and H2/H2 (30.0%).
CONCLUSIONS: H1/H1 of the human PXR gene had weaker basal transcriptional activity but greater inducible transcriptional activity to CYP3A4 than H1/H2 and H2/H2.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19173680      PMCID: PMC2670384          DOI: 10.1111/j.1365-2125.2008.03344.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  26 in total

1.  Population distribution and effects on drug metabolism of a genetic variant in the 5' promoter region of CYP3A4.

Authors:  S E Ball; J Scatina; J Kao; G M Ferron; R Fruncillo; P Mayer; I Weinryb; M Guida; P J Hopkins; N Warner; J Hall
Journal:  Clin Pharmacol Ther       Date:  1999-09       Impact factor: 6.875

Review 2.  International Union of Pharmacology. LXII. The NR1H and NR1I receptors: constitutive androstane receptor, pregnene X receptor, farnesoid X receptor alpha, farnesoid X receptor beta, liver X receptor alpha, liver X receptor beta, and vitamin D receptor.

Authors:  David D Moore; Shigeaki Kato; Wen Xie; David J Mangelsdorf; Daniel R Schmidt; Rui Xiao; Steven A Kliewer
Journal:  Pharmacol Rev       Date:  2006-12       Impact factor: 25.468

Review 3.  PXR and CAR: nuclear receptors which play a pivotal role in drug disposition and chemical toxicity.

Authors:  Lesley A Stanley; Brian C Horsburgh; Jillian Ross; Nico Scheer; C Roland Wolf
Journal:  Drug Metab Rev       Date:  2006       Impact factor: 4.518

Review 4.  Noninvasive tests of CYP3A enzymes.

Authors:  P B Watkins
Journal:  Pharmacogenetics       Date:  1994-08

5.  Functional characterization of a novel polymorphism of pregnane X receptor, Q158K, in Chinese subjects.

Authors:  Yun-Ping Lim; Chin-Hung Liu; Lih-Jen Shyu; Jin-Ding Huang
Journal:  Pharmacogenet Genomics       Date:  2005-05       Impact factor: 2.089

Review 6.  Pregnane X receptor: promiscuous regulator of detoxification pathways.

Authors:  Marko Matic; Andre Mahns; Maria Tsoli; Anthony Corradin; Patsie Polly; Graham R Robertson
Journal:  Int J Biochem Cell Biol       Date:  2006-09-14       Impact factor: 5.085

7.  A steroid receptor coactivator, SRA, functions as an RNA and is present in an SRC-1 complex.

Authors:  R B Lanz; N J McKenna; S A Onate; U Albrecht; J Wong; S Y Tsai; M J Tsai; B W O'Malley
Journal:  Cell       Date:  1999-04-02       Impact factor: 41.582

8.  Identification of NR1I2 genetic variation using resequencing.

Authors:  Cristi R King; Ming Xiao; Jinsheng Yu; Matthew R Minton; Nicholas J Addleman; Derek J Van Booven; Pui-Yan Kwok; Howard L McLeod; Sharon Marsh
Journal:  Eur J Clin Pharmacol       Date:  2007-04-03       Impact factor: 2.953

Review 9.  P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR, and PPAR.

Authors:  D J Waxman
Journal:  Arch Biochem Biophys       Date:  1999-09-01       Impact factor: 4.013

10.  Pharmacokinetics of oral nifedipine in different populations.

Authors:  G Castañeda-Hernández; C Hoyo-Vadillo; J A Palma-Aguirre; F J Flores-Murrieta
Journal:  J Clin Pharmacol       Date:  1993-02       Impact factor: 3.126

View more
  12 in total

Review 1.  Drug interactions with herbal medicines.

Authors:  Shaojun Shi; Ulrich Klotz
Journal:  Clin Pharmacokinet       Date:  2012-02-01       Impact factor: 6.447

2.  A physiome interoperability roadmap for personalized drug development.

Authors:  Simon Thomas; Katherine Wolstencroft; Bernard de Bono; Peter J Hunter
Journal:  Interface Focus       Date:  2016-04-06       Impact factor: 3.906

Review 3.  Psychotropic drug-drug interactions involving P-glycoprotein.

Authors:  Yumiko Akamine; Norio Yasui-Furukori; Ichiro Ieiri; Tsukasa Uno
Journal:  CNS Drugs       Date:  2012-11       Impact factor: 5.749

Review 4.  Interactions between herbal medicines and prescribed drugs: an updated systematic review.

Authors:  Angelo A Izzo; Edzard Ernst
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 5.  Herb-drug interactions with St John's wort (Hypericum perforatum): an update on clinical observations.

Authors:  Francesca Borrelli; Angelo A Izzo
Journal:  AAPS J       Date:  2009-10-27       Impact factor: 4.009

Review 6.  Cytochrome P450 enzyme mediated herbal drug interactions (Part 1).

Authors:  Sompon Wanwimolruk; Virapong Prachayasittikul
Journal:  EXCLI J       Date:  2014-04-02       Impact factor: 4.068

7.  Genetic markers in CYP2C19 and CYP2B6 for prediction of cyclophosphamide's 4-hydroxylation, efficacy and side effects in Chinese patients with systemic lupus erythematosus.

Authors:  Wenying Shu; Su Guan; Xiuyan Yang; Liuqin Liang; Jiali Li; Zhuojia Chen; Yu Zhang; Lingyan Chen; Xueding Wang; Min Huang
Journal:  Br J Clin Pharmacol       Date:  2015-12-25       Impact factor: 4.335

8.  Study of the upregulation of the activity of cytochrome P450 3A isoforms by Astragalus injection and Astragalus granules in rats and in cells.

Authors:  Yongli Zhang; Ling Huang; Huichang Bi; Yuqiang Cui; Jingqing Li; Xiangsheng Wang; Xiaoling Qin; Jiangying Chen; Min Huang
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2012-07-14       Impact factor: 2.441

Review 9.  Pharmacogenomics and herb-drug interactions: merge of future and tradition.

Authors:  Mou-Ze Liu; Yue-Li Zhang; Mei-Zi Zeng; Fa-Zhong He; Zhi-Ying Luo; Jian-Quan Luo; Jia-Gen Wen; Xiao-Ping Chen; Hong-Hao Zhou; Wei Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2015-03-02       Impact factor: 2.629

10.  Genetic Variants of Pregnane X Receptor (PXR) and CYP2B6 Affect the Induction of Bupropion Hydroxylation by Sodium Ferulate.

Authors:  Lichen Gao; Yijing He; Jie Tang; Jiye Yin; Zhengyu Huang; Fangqun Liu; Dongsheng Ouyang; Xiaoping Chen; Wei Zhang; Zhaoqian Liu; Honghao Zhou
Journal:  PLoS One       Date:  2013-06-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.